Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma

Luca Arcaini, Lucia Morello, Alessandra Tucci, Chiara Rusconi, Marco Ladetto, Sara Rattotti, Maurizio Bonfichi, Chiara Bottelli, Cristina Gabutti, Paolo Bernasconi, Marzia Varettoni, Manuel Gotti, Daniela Troletti, Maria Luisa Guerrera, Valeria Fiaccadori, Roberta Sciarra, Virginia Valeria Ferretti, Emilio Paolo Alessandrino, Giuseppe Rossi, Enrica Morra

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.

Original languageEnglish
Pages (from-to)230-234
Number of pages5
JournalAmerican Journal of Hematology
Volume90
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Follicular Lymphoma
Stem Cell Transplantation
Stem Cells
Drug Therapy
Autologous Transplantation
Anthracyclines
Vincristine
Prednisone
Cyclophosphamide
Histology

ASJC Scopus subject areas

  • Hematology

Cite this

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. / Arcaini, Luca; Morello, Lucia; Tucci, Alessandra; Rusconi, Chiara; Ladetto, Marco; Rattotti, Sara; Bonfichi, Maurizio; Bottelli, Chiara; Gabutti, Cristina; Bernasconi, Paolo; Varettoni, Marzia; Gotti, Manuel; Troletti, Daniela; Guerrera, Maria Luisa; Fiaccadori, Valeria; Sciarra, Roberta; Ferretti, Virginia Valeria; Alessandrino, Emilio Paolo; Rossi, Giuseppe; Morra, Enrica.

In: American Journal of Hematology, Vol. 90, No. 3, 01.03.2015, p. 230-234.

Research output: Contribution to journalArticle

Arcaini, Luca ; Morello, Lucia ; Tucci, Alessandra ; Rusconi, Chiara ; Ladetto, Marco ; Rattotti, Sara ; Bonfichi, Maurizio ; Bottelli, Chiara ; Gabutti, Cristina ; Bernasconi, Paolo ; Varettoni, Marzia ; Gotti, Manuel ; Troletti, Daniela ; Guerrera, Maria Luisa ; Fiaccadori, Valeria ; Sciarra, Roberta ; Ferretti, Virginia Valeria ; Alessandrino, Emilio Paolo ; Rossi, Giuseppe ; Morra, Enrica. / Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. In: American Journal of Hematology. 2015 ; Vol. 90, No. 3. pp. 230-234.
@article{2653c6091fcd40ccaf09533eb1be86f8,
title = "Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma",
abstract = "High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14{\%} of patients had grade 3A histology. Debulking chemotherapy produced CR in 16{\%} and PR in 71{\%}, while 13{\%} of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60{\%} and PR in 35{\%}; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0{\%}. The 5-year PFS was 54{\%} and the 5-year OS was 83{\%}. After a median f-up of 6.7 years (range 1.5-13.6), 54{\%} are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.",
author = "Luca Arcaini and Lucia Morello and Alessandra Tucci and Chiara Rusconi and Marco Ladetto and Sara Rattotti and Maurizio Bonfichi and Chiara Bottelli and Cristina Gabutti and Paolo Bernasconi and Marzia Varettoni and Manuel Gotti and Daniela Troletti and Guerrera, {Maria Luisa} and Valeria Fiaccadori and Roberta Sciarra and Ferretti, {Virginia Valeria} and Alessandrino, {Emilio Paolo} and Giuseppe Rossi and Enrica Morra",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/ajh.23919",
language = "English",
volume = "90",
pages = "230--234",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma

AU - Arcaini, Luca

AU - Morello, Lucia

AU - Tucci, Alessandra

AU - Rusconi, Chiara

AU - Ladetto, Marco

AU - Rattotti, Sara

AU - Bonfichi, Maurizio

AU - Bottelli, Chiara

AU - Gabutti, Cristina

AU - Bernasconi, Paolo

AU - Varettoni, Marzia

AU - Gotti, Manuel

AU - Troletti, Daniela

AU - Guerrera, Maria Luisa

AU - Fiaccadori, Valeria

AU - Sciarra, Roberta

AU - Ferretti, Virginia Valeria

AU - Alessandrino, Emilio Paolo

AU - Rossi, Giuseppe

AU - Morra, Enrica

PY - 2015/3/1

Y1 - 2015/3/1

N2 - High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.

AB - High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT. Median age was 52 years; 14% of patients had grade 3A histology. Debulking chemotherapy produced CR in 16% and PR in 71%, while 13% of patients progressed. After rituximab, cyclophosphamide, vincristine, prednisone (R-COP), CR was obtained in 60% and PR in 35%; 118 patients successfully mobilized PBSC and 117 proceeded to ASCT. The harvest in all the 32 molecularly informative patients was bcl-2 negative. TRM was 0%. The 5-year PFS was 54% and the 5-year OS was 83%. After a median f-up of 6.7 years (range 1.5-13.6), 54% are still in CR. These data show that prolonged PFS is achievable in relapsed/refractory patients with high dose autologous transplantation of in vivo purged progenitor cells.

UR - http://www.scopus.com/inward/record.url?scp=84923026608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923026608&partnerID=8YFLogxK

U2 - 10.1002/ajh.23919

DO - 10.1002/ajh.23919

M3 - Article

C2 - 25502635

AN - SCOPUS:84923026608

VL - 90

SP - 230

EP - 234

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -